regulatory

News

FDA turns down Lilly’s eczema drug lebrikizumab

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop

News

Pharma says EU chemical ban could devastate manufacturing

A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind

Sales & Marketing

Prescription for success: How creativity is the secret ingre...

Can you imagine a world where pharmaceutical marketing was as thrilling as a sloth hosting a speed dating event?

News

FDA advisors unconvinced by BrainStorm’s ALS cell therapy

An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su

News

Travere weaker after Filspari fails confirmatory trial

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspar

News

FDA declines to approve needle-free epinephrine from ARS

Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product,

FDA turns down Lilly’s eczema drug lebrikizumab

Pharma says EU chemical ban could devastate manufacturing

Prescription for success: How creativity is the secret ingre...

FDA advisors unconvinced by BrainStorm’s ALS cell therapy

Travere weaker after Filspari fails confirmatory trial

FDA declines to approve needle-free epinephrine from ARS

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

regulatory

Editor's Picks